SURAKSHA DIAGNOSTIC LTD

Suraksha Diagnostic Limited reported a strong start to FY '27 during its earnings conference call held on August 13, 2026. Management highlighted a year-on-year revenue growth of 21%, EBITDA growth of 28%, and a PAT growth of 40% for Q1 FY '27. The company emphasized its focus on expanding clinical capabilities and enhancing patient experience. Suraksha Genomics showed significant growth, with a 136% increase in revenue, and management introduced new tests, including an Alzheimer’s blood test. The company expanded its network by commissioning new centers in Jharkhand and Tripura. Management provided financial details, noting total income of INR 887 million and an EBITDA margin of 36%. They expressed confidence in sustaining margins and profitability as new centers mature. The call concluded with management reaffirming their commitment to service excellence and innovation in diagnostics.

Management emphasized strong financial performance and growth initiatives.